ReNeuron Group - Exploiting the potential of cell therapy
ReNeuron has refocussed onto its human retinal progenitor cell (hRPC) as shown in the last business update and in the FY20 results. hRPC, now the lead project, show a consistent and robust sustained averaged response at the one million cell dose. The next dose level, two million cells in nine patients, could start this autumn. A pivotal study could be initiated in 2022. ReNeuron is starting to create multiple partnering opportunities from its core technologies. We have revised our valuation to £170m from £107m.Reneuron Group researches and develops therapies using stem cells. Co.'s products include: CTX cells for stroke disability, which is its therapeutic candidate for the treatment of patients left disabled by the effects of a stroke; human retinal progenitor cells (hRPCs) for retinitis pigmentosa (RP), which is its therapeutic hRPC candidate for the treatment of RP, a blindness-causing disease of the retina; hRPCs for cone-rod dystrophy, which is a hRPC therapeutic candidate across a range of genetic diseases of the eye; and CTX-derived exosomes, which is its exosomes nanomedicine platform that generates early pre-clinical data in cancer.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.